keyword
https://read.qxmd.com/read/30913309/high-intensity-end-of-life-care-among-children-adolescents-and-young-adults-with-cancer-who-die-in-the-hospital-a-population-based-study-from-the-french-national-hospital-database
#21
JOURNAL ARTICLE
Gabriel Revon-Rivière, Vanessa Pauly, Karine Baumstarck, Cecile Bernard, Nicolas André, Jean-Claude Gentet, Catherine Seyler, Guillaume Fond, Veronica Orleans, Gérard Michel, Pascal Auquier, Laurent Boyer
BACKGROUND: Efforts to improve the quality of end-of-life (EOL) care depend on better knowledge of the care that children, adolescents, and young adults with cancer receive, including high-intensity EOL (HI-EOL) care. The objective was to assess the rates of HI-EOL care in this population and to determine patient- and hospital-related predictors of HI-EOL from the French national hospital database. METHODS: This was a population-based, retrospective study of a cohort of patients aged 0 to 25 years at the time of death who died at hospital as a result of cancer in France between 2014 and 2016...
March 26, 2019: Cancer
https://read.qxmd.com/read/30319400/metronomic-four-drug-regimen-has-anti-tumor-activity-in-pediatric-low-grade-glioma-the-results-of-a-phase-ii-clinical-trial
#22
JOURNAL ARTICLE
Arnauld Verschuur, Marie-Amélie Heng-Maillard, Philippe Dory-Lautrec, Romain Truillet, Elisabeth Jouve, Pascal Chastagner, Pierre Leblond, Isabelle Aerts, Stéphane Honoré, Natasha Entz-Werle, Nicolas Sirvent, Jean-Claude Gentet, Nadège Corradini, Nicolas André
Background: Metronomic chemotherapy (MC) is defined as the frequent administration of chemotherapy at doses below the maximal tolerated dose and with no prolonged drug-free break. MC has shown its efficacy in adult tumor types such as breast and ovarian cancer and has to some extent been studied in pediatrics. Objective: To assess the anti-tumor activity and toxicity of a four-drug metronomic regimen in relapsing/refractory pediatric brain tumors (BT) with progression-free survival (PFS) after two cycles as primary endpoint...
2018: Frontiers in Pharmacology
https://read.qxmd.com/read/30188789/high-dose-chemotherapy-and-blood-autologous-stem-cell-rescue-compared-with-standard-chemotherapy-in-localized-high-risk-ewing-sarcoma-results-of-euro-e-w-i-n-g-99-and-ewing-2008
#23
JOURNAL ARTICLE
Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, Gwénaël Le Teuff, Bernadette Brennan, Nathalie Gaspar, Douglas S Hawkins, Susanne Amler, Sebastian Bauer, Stefan Bielack, Jean-Yves Blay, Stefan Burdach, Marie-Pierre Castex, Dagmar Dilloo, Angelika Eggert, Hans Gelderblom, Jean-Claude Gentet, Wolfgang Hartmann, Wolf-Achim Hassenpflug, Lars Hjorth, Marta Jimenez, Thomas Klingebiel, Udo Kontny, Jarmila Kruseova, Ruth Ladenstein, Valerie Laurence, Cyril Lervat, Perrine Marec-Berard, Sandrine Marreaud, Jean Michon, Bruce Morland, Michael Paulussen, Andreas Ranft, Peter Reichardt, Hendrik van den Berg, Keith Wheatley, Ian Judson, Ian Lewis, Alan Craft, Heribert Juergens, Odile Oberlin
Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine, dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger than 50 years of age with poor histologic response (≥ 10% viable cells) after receiving vincristine, ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis ≥ 200 mL if unresected, or initially resected, or resected after radiotherapy...
September 6, 2018: Journal of Clinical Oncology
https://read.qxmd.com/read/29791011/a-pharmacokinetic-and-pharmacogenetic-analysis-of-osteosarcoma-patients-treated-with-high-dose-methotrexate-data-from-the-os2006-sarcoma-09-trial
#24
JOURNAL ARTICLE
Gabrielle Lui, Jean-Marc Treluyer, Brice Fresneau, Sophie Piperno-Neumann, Nathalie Gaspar, Nadège Corradini, Jean-Claude Gentet, Perrine Marec Berard, Valérie Laurence, Pascale Schneider, Natacha Entz-Werle, Hélène Pacquement, Frédéric Millot, Sophie Taque, Claire Freycon, Cyril Lervat, Marie Cécile Le Deley, Céline Mahier Ait Oukhatar, Laurence Brugieres, Gwénaël Le Teuff, Naïm Bouazza
Growing evidence suggests that polymorphisms of genes coding for transporters or enzymes may partially explain the large between subject variability reported for methotrexate (MTX) pharmacokinetics (PK). This prospective study aimed to develop a population PK-pharmacogenetic model to evaluate the part of between-subject variability due to single-nucleotide polymorphisms (SNPs) in transporters and enzyme genes implicated in MTX distribution and elimination. MTX concentrations and 54 SNPs (located in ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCG2, SLC19A1, SLCO1B1, and UGT1A1 genes) were analyzed in patients treated with MTX included in the OS2006/sarcoma-09 trial (a multicenter, open-label, phase III trial, ClinicalTrials...
December 2018: Journal of Clinical Pharmacology
https://read.qxmd.com/read/29515801/recurrent-extraneural-sonic-hedgehog-medulloblastoma-exhibiting-sustained-response-to-vismodegib-and-temozolomide-monotherapies-and-inter-metastatic-molecular-heterogeneity-at-progression
#25
JOURNAL ARTICLE
Gregorio J Petrirena, Julien Masliah-Planchon, Quentin Sala, Bertrand Pourroy, Didier Frappaz, Emeline Tabouret, Thomas Graillon, Jean-Claude Gentet, Olivier Delattre, Olivier Chinot, Laetitia Padovani
Background: Response to targeting and non-targeting agents is variable and molecular information remains poorly described in patients with recurrent sonic-hedgehog-driven medulloblastoma (SHH-MB). Materials and Methods: Clinical and PET/CT findings during treatment with successive hedgehog antagonists and temozolomide monotherapies are described in a heavily pre-treated patient with recurrent extraneural metastases from PTCH1 mutated/ wild type smoothened ( SMO ) CNS SHH-MB...
February 9, 2018: Oncotarget
https://read.qxmd.com/read/29190507/results-of-methotrexate-etoposide-ifosfamide-based-regimen-m-ei-in-osteosarcoma-patients-included-in-the-french-os2006-sarcome-09-study
#26
RANDOMIZED CONTROLLED TRIAL
Nathalie Gaspar, Bob-Valéry Occean, Hélène Pacquement, Emmanuelle Bompas, Corine Bouvier, Hervé J Brisse, Marie-Pierre Castex, Nadir Cheurfa, Nadège Corradini, Jessy Delaye, Natacha Entz-Werlé, Jean-Claude Gentet, Antoine Italiano, Cyril Lervat, Perrine Marec-Berard, Eric Mascard, Françoise Redini, Laure Saumet, Claudine Schmitt, Marie-Dominique Tabone, Cécile Verite-Goulard, Marie-Cécile Le Deley, Sophie Piperno-Neumann, Laurence Brugieres
BACKGROUND: In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum). In France, the standard preoperative chemotherapy for children/adolescents combines M and etoposide-ifosfamide (EI), based on the OS94-trial. We report the safety and efficacy results of patients ≤25 years treated with preoperative M-EI regimen enroled in the French OS2006-study, between 2007 and 2014. METHODS: Treatment comprised preoperative chemotherapy with the 7 M-courses and 2 EI-courses, then surgery and postoperative chemotherapy assigned by risk's groups: standard-risk (good histological response without metastases) received 12 M-courses, 3 EI-courses; high-risk (poor histologic response, initial metastases or unresectable primary) received 5 M-courses alternated with 5 AP-courses...
January 2018: European Journal of Cancer
https://read.qxmd.com/read/28738258/open-label-multicentre-randomised-phase-ii-study-of-the-epssg-and-the-itcc-evaluating-the-addition-of-bevacizumab-to-chemotherapy-in-childhood-and-adolescent-patients-with-metastatic-soft-tissue-sarcoma-the-bernie-study
#27
RANDOMIZED CONTROLLED TRIAL
Julia C Chisholm, Johannes H M Merks, Michela Casanova, Gianni Bisogno, Daniel Orbach, Jean-Claude Gentet, Anne-Sophie Thomassin-Defachelles, Pascal Chastagner, Stephen Lowis, Milind Ronghe, Kieran McHugh, Rick R van Rijn, Magalie Hilton, Jeanette Bachir, Sabine Fürst-Recktenwald, Birgit Geoerger, Odile Oberlin
PURPOSE: We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). PATIENTS AND METHODS: Eligible patients aged ≥6 months to <18 years were randomised to receive induction chemotherapy (four cycles of IVADo + five cycles of IVA, ±bevacizumab), surgery and/or radiotherapy, followed by maintenance chemotherapy (12 cycles of low-dose cyclophosphamide + vinorelbine, ±bevacizumab)...
September 2017: European Journal of Cancer
https://read.qxmd.com/read/28619014/prognostic-impact-of-blood-and-urinary-angiogenic-factor-levels-at-diagnosis-and-during-treatment-in-patients-with-osteosarcoma-a-prospective-study
#28
JOURNAL ARTICLE
Marie-Dominique Tabone, Laurence Brugières, Sophie Piperno-Neumann, Marie-Ange Selva, Perrine Marec-Bérard, Hélène Pacquement, Cyril Lervat, Nadège Corradini, Jean-Claude Gentet, Rémy Couderc, Aurélie Chevance, Céline Mahier-Ait Oukhatar, Natacha Entz-Werle, Jean-Yves Blay, Marie-Cecile Le Deley
BACKGROUND: Angiogenesis is essential for the progression and metastatic spread of solid tumours. Expression of vascular endothelial growth factor (VEGF) has been linked to poor survival among osteosarcoma patients but the clinical relevance of monitoring blood and urine angiogenic factors is uncertain. The aim of this study was to determine the prognostic significance of blood VEGF and blood and urinary basic fibroblast growth factor (bFGF) levels in osteosarcoma patients, both at diagnosis and during treatment...
June 15, 2017: BMC Cancer
https://read.qxmd.com/read/28560702/hybrid-intracerebral-probe-with-integrated-bare-led-chips-for-optogenetic-studies
#29
JOURNAL ARTICLE
Suleman Ayub, Luc J Gentet, Richárd Fiáth, Michael Schwaerzle, Mélodie Borel, François David, Péter Barthó, István Ulbert, Oliver Paul, Patrick Ruther
This article reports on the development, i.e., the design, fabrication, and validation of an implantable optical neural probes designed for in vivo experiments relying on optogenetics. The probes comprise an array of ten bare light-emitting diode (LED) chips emitting at a wavelength of 460 nm and integrated along a flexible polyimide-based substrate stiffened using a micromachined ladder-like silicon structure. The resulting mechanical stiffness of the slender, 250-μm-wide, 65-μm-thick, and 5- and 8-mm-long probe shank facilitates its implantation into neural tissue...
September 2017: Biomedical Microdevices
https://read.qxmd.com/read/27608849/prognostic-value-of-the-hippo-pathway-transcriptional-coactivators-yap-taz-and-%C3%AE-1-integrin-in-conventional-osteosarcoma
#30
JOURNAL ARTICLE
Corinne Bouvier, Nicolas Macagno, Quy Nguyen, Anderson Loundou, Carine Jiguet-Jiglaire, Jean-Claude Gentet, Jean-Luc Jouve, Alexandre Rochwerger, Jean-Camille Mattei, Daniel Bouvard, Sébastien Salas
INTRODUCTION: Currently, very few studies are available concerning the mammalian Hippo pathway in bone sarcomas. YAP/TAZ transcription co-activators are key downstream effectors of this pathway and may also have oncogenic properties. Additionally, recent in-vitro experiments showed that expression of β1-integrin promoted metastasis in osteosarcomas. This study investigated the expression of YAP/TAZ and β1-integrin in human osteosarcomas. MATERIALS AND METHODS: We performed automated immunohistochemistry on tissue-microarrays (TMA) in which 69 conventional osteosarcomas biopsies performed prior to chemotherapy were embedded...
October 4, 2016: Oncotarget
https://read.qxmd.com/read/27324280/zoledronate-in-combination-with-chemotherapy-and-surgery-to-treat-osteosarcoma-os2006-a-randomised-multicentre-open-label-phase-3-trial
#31
RANDOMIZED CONTROLLED TRIAL
Sophie Piperno-Neumann, Marie-Cécile Le Deley, Françoise Rédini, Hélène Pacquement, Perrine Marec-Bérard, Philippe Petit, Hervé Brisse, Cyril Lervat, Jean-Claude Gentet, Natacha Entz-Werlé, Antoine Italiano, Nadège Corradini, Emmanuelle Bompas, Nicolas Penel, Marie-Dominique Tabone, Anne Gomez-Brouchet, Jean-Marc Guinebretière, Eric Mascard, François Gouin, Aurélie Chevance, Naïma Bonnet, Jean-Yves Blay, Laurence Brugières
BACKGROUND: Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma. METHODS: In this randomised, multicentre, open-label, phase 3 trial (OS2006), patients aged between 5 years and 50 years with newly diagnosed high-grade osteosarcoma were randomly assigned to receive standard chemotherapy with or without ten zoledronate intravenous infusions (four preoperative and six postoperative)...
August 2016: Lancet Oncology
https://read.qxmd.com/read/27037940/can-metronomic-maintenance-with-weekly-vinblastine-prevent-early-relapse-progression-after-bevacizumab-irinotecan-in-children-with-low-grade-glioma
#32
JOURNAL ARTICLE
Marie Amélie Heng, Laetitia Padovani, Philippe Dory-Lautrec, Jean Claude Gentet, Arnaud Verschuur, Eddy Pasquier, Dominique Figarella-Branger, Didier Scavarda, Nicolas André
The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low-grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan-bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow-up of 23 months after the end of the bevacizumab-irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan-bevacizumab can improve progression-free survival in children with LGG...
July 2016: Cancer Medicine
https://read.qxmd.com/read/26890123/membrane-potential-dynamics-of-spontaneous-and-visually-evoked-gamma-activity-in-v1-of-awake-mice
#33
JOURNAL ARTICLE
Quentin Perrenoud, Cyriel M A Pennartz, Luc J Gentet
Cortical gamma activity (30-80 Hz) is believed to play important functions in neural computation and arises from the interplay of parvalbumin-expressing interneurons (PV) and pyramidal cells (PYRs). However, the subthreshold dynamics underlying its emergence in the cortex of awake animals remain unclear. Here, we characterized the intracellular dynamics of PVs and PYRs during spontaneous and visually evoked gamma activity in layers 2/3 of V1 of awake mice using targeted patch-clamp recordings and synchronous local field potentials (LFPs)...
February 2016: PLoS Biology
https://read.qxmd.com/read/26834582/cell-type-and-state-dependent-synchronization-among-rodent-somatosensory-visual-perirhinal-cortex-and-hippocampus-ca1
#34
JOURNAL ARTICLE
Martin Vinck, Jeroen J Bos, Laura A Van Mourik-Donga, Krista T Oplaat, Gerbrand A Klein, Jadin C Jackson, Luc J Gentet, Cyriel M A Pennartz
Beta and gamma rhythms have been hypothesized to be involved in global and local coordination of neuronal activity, respectively. Here, we investigated how cells in rodent area S1BF are entrained by rhythmic fluctuations at various frequencies within the local area and in connected areas, and how this depends on behavioral state and cell type. We performed simultaneous extracellular field and unit recordings in four connected areas of the freely moving rat (S1BF, V1M, perirhinal cortex, CA1). S1BF spiking activity was strongly entrained by both beta and gamma S1BF oscillations, which were associated with deactivations and activations, respectively...
2015: Frontiers in Systems Neuroscience
https://read.qxmd.com/read/26541413/off-label-use-of-targeted-therapies-in-osteosarcomas-data-from-the-french-registry-outc-s-observatoire-de-l-utilisation-des-th%C3%A3-rapies-cibl%C3%A3-es-dans-les-sarcomes
#35
JOURNAL ARTICLE
Mathilde Penel-Page, Isabelle Ray-Coquard, Julie Larcade, Magali Girodet, Laure Bouclier, Muriel Rogasik, Nadège Corradini, Natacha Entz-Werle, Laurence Brugieres, Julien Domont, Cyril Lervat, Sophie Piperno-Neumann, Helène Pacquement, Jacques-Olivier Bay, Jean-Claude Gentet, Antoine Thyss, Loic Chaigneau, Bérangère Narciso, Helène Cornille, Jean-Yves Blay, Perrine Marec-Bérard
BACKGROUND: The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group--Bone Tumor Study Group (GSF-GETO) national registry. METHODS: All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed. RESULTS: Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs...
November 5, 2015: BMC Cancer
https://read.qxmd.com/read/26489463/whisking-related-changes-in-neuronal-firing-and-membrane-potential-dynamics-in-the-somatosensory-thalamus-of-awake-mice
#36
JOURNAL ARTICLE
Nadia Urbain, Paul A Salin, Paul-Antoine Libourel, Jean-Christophe Comte, Luc J Gentet, Carl C H Petersen
The thalamus transmits sensory information to the neocortex and receives neocortical, subcortical, and neuromodulatory inputs. Despite its obvious importance, surprisingly little is known about thalamic function in awake animals. Here, using intracellular and extracellular recordings in awake head-restrained mice, we investigate membrane potential dynamics and action potential firing in the two major thalamic nuclei related to whisker sensation, the ventral posterior medial nucleus (VPM) and the posterior medial group (Pom), which receive distinct inputs from brainstem and neocortex...
October 27, 2015: Cell Reports
https://read.qxmd.com/read/26284122/pilot-evaluation-of-physical-and-psychological-effects-of-a-physical-trek-programme-including-a-dog-sledding-expedition-in-children-and-teenagers-with-cancer
#37
JOURNAL ARTICLE
Clothilde Vallet, Nicolas André, Jean-Claude Gentet, Arnauld Verschuur, Gérard Michel, Frédéric Sotteau, Cécile Martha, Laurent Grélot
AIM OF THE STUDY: To evaluate the feasibility and to measure the effects of a six-week-long adapted physical activity programme (APAP), including 5 days of intense dog sledding, on the physical and psychological health of children and adolescents treated for cancer. METHODS: Eleven children and teenagers (4 girls, 7 boys; mean age 14.3 ± 2.9 years) participated in this monocentric pilot programme of adapted physical activities from February 2013 to March 2013. Seven were still on treatment...
2015: Ecancermedicalscience
https://read.qxmd.com/read/26115930/phase-i-study-of-non-pegylated-liposomal-doxorubicin-in-children-with-recurrent-refractory-high-grade-glioma
#38
JOURNAL ARTICLE
Pascal Chastagner, Bénédicte Devictor, Birgit Geoerger, Isabelle Aerts, Pierre Leblond, Didier Frappaz, Jean-Claude Gentet, Serge Bracard, Nicolas André
PURPOSE: To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. METHODS: Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. Cohorts of at least three patients each received escalating doses of Myocet® starting at 60 mg/m(2) at 3-week intervals, administered intravenously over 1 h, and then doses were escalated to 75 mg/m(2) corresponding to the adult RD...
August 2015: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/26112583/-supporting-children-with-cancer-experience-of-the-smile-at-life-association
#39
JOURNAL ARTICLE
J-C Gentet, C Vallet, G Michel, N André, A Verschuur, M-N Bonfanti, S Faure, F Sotteau
No abstract text is available yet for this article.
May 2015: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://read.qxmd.com/read/25420707/the-off-label-use-of-targeted-therapies-in-sarcomas-the-outc-s-program
#40
JOURNAL ARTICLE
Lauriane Eberst, Claire Cropet, Axel Le Cesne, Patricia Pautier, Nicolas Penel, Antoine Adenis, Christine Chevreau, Jacques-Olivier Bay, Olivier Collard, Didier Cupissol, Florence Duffaud, Jean-Claude Gentet, Sophie Piperno-Neumann, Perrine Marec-Berard, Emmanuelle Bompas, Antoine Thyss, Loic Chaigneau, Philippe Cassier, François Bertucci, Jean-Yves Blay, Isabelle Ray-Coquard
BACKGROUND: Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients treated with off-label TTs. METHODS: Every consecutive sarcoma-patient receiving an off-label TT outside a clinical trial was included. The objective was to describe this patient efficacy and safety data in routine practice...
November 24, 2014: BMC Cancer
keyword
keyword
96885
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.